Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1982 1
1986 1
1987 2
1989 1
1990 3
1991 1
1992 5
1993 3
1994 2
1995 3
1996 4
1997 1
1998 1
1999 1
2000 1
2001 3
2002 3
2003 2
2004 9
2005 6
2006 13
2007 6
2008 7
2009 14
2010 18
2011 28
2012 21
2013 31
2014 29
2015 71
2016 57
2017 61
2018 37
2019 57
2020 83
2021 56
2022 23
2023 21
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

662 results

Results by year

Filters applied: . Clear all
Page 1
The value of antimicrobial peptides in the age of resistance.
Magana M, Pushpanathan M, Santos AL, Leanse L, Fernandez M, Ioannidis A, Giulianotti MA, Apidianakis Y, Bradfute S, Ferguson AL, Cherkasov A, Seleem MN, Pinilla C, de la Fuente-Nunez C, Lazaridis T, Dai T, Houghten RA, Hancock REW, Tegos GP. Magana M, et al. Lancet Infect Dis. 2020 Sep;20(9):e216-e230. doi: 10.1016/S1473-3099(20)30327-3. Epub 2020 Jul 9. Lancet Infect Dis. 2020. PMID: 32653070 Review.
Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial.
Kaasch AJ, López-Cortés LE, Rodríguez-Baño J, Cisneros JM, Dolores Navarro M, Fätkenheuer G, Jung N, Rieg S, Lepeule R, Coutte L, Bernard L, Lemaignen A, Kösters K, MacKenzie CR, Soriano A, Hagel S, Fantin B, Lafaurie M, Talarmin JP, Dinh A, Guimard T, Boutoille D, Welte T, Reuter S, Kluytmans J, Martin ML, Forestier E, Stocker H, Vitrat V, Tattevin P, Rommerskirchen A, Noret M, Adams A, Kern WV, Hellmich M, Seifert H; SABATO study group. Kaasch AJ, et al. Lancet Infect Dis. 2024 May;24(5):523-534. doi: 10.1016/S1473-3099(23)00756-9. Epub 2024 Jan 17. Lancet Infect Dis. 2024. PMID: 38244557 Clinical Trial.
In the oral switch group, 36 (34%) of 107 participants in the safety population had at least one serious adverse event compared with 27 (26%) of 103 participants in the intravenous group (p=0.29). ...
In the oral switch group, 36 (34%) of 107 participants in the safety population had at least one serious adverse event compared with …
Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM.
Chen SC, Perfect J, Colombo AL, Cornely OA, Groll AH, Seidel D, Albus K, de Almedia JN Jr, Garcia-Effron G, Gilroy N, Lass-Flörl C, Ostrosky-Zeichner L, Pagano L, Papp T, Rautemaa-Richardson R, Salmanton-García J, Spec A, Steinmann J, Arikan-Akdagli S, Arenz DE, Sprute R, Duran-Graeff L, Freiberger T, Girmenia C, Harris M, Kanj SS, Roudbary M, Lortholary O, Meletiadis J, Segal E, Tuon FF, Wiederhold N, Bicanic T, Chander J, Chen YC, Hsueh PR, Ip M, Munoz P, Spriet I, Temfack E, Thompson L, Tortorano AM, Velegraki A, Govender NP. Chen SC, et al. Lancet Infect Dis. 2021 Dec;21(12):e375-e386. doi: 10.1016/S1473-3099(21)00203-6. Epub 2021 Aug 19. Lancet Infect Dis. 2021. PMID: 34419208 Review.
Because there is less clinical experience of patients with rare yeast infections and studies on these patients were not randomised, nor were groups compared, most recommendations are not robust in their validation but represent insights by use of expert opinions and in-vit …
Because there is less clinical experience of patients with rare yeast infections and studies on these patients were not randomised, nor were …
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Ráčil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JH, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJGT; VITAL and FungiScope Mucormycosis Investigators. Marty FM, et al. Lancet Infect Dis. 2016 Jul;16(7):828-837. doi: 10.1016/S1473-3099(16)00071-2. Epub 2016 Mar 9. Lancet Infect Dis. 2016. PMID: 26969258 Clinical Trial.
We assessed the efficacy and safety of isavuconazole for treatment of mucormycosis and compared its efficacy with amphotericin B in a matched case-control analysis. ...
We assessed the efficacy and safety of isavuconazole for treatment of mucormycosis and compared its efficacy with amphotericin B in a …
Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial.
Tsalik EL, Rouphael NG, Sadikot RT, Rodriguez-Barradas MC, McClain MT, Wilkins DM, Woods CW, Swamy GK, Walter EB, El Sahly HM, Keitel WA, Mulligan MJ, Tuyishimire B, Serti E, Hamasaki T, Evans SR, Ghazaryan V, Lee MS, Lautenbach E; TRAP-LRTI Study Group; Antibacterial Resistance Leadership Group. Tsalik EL, et al. Lancet Infect Dis. 2023 Apr;23(4):484-495. doi: 10.1016/S1473-3099(22)00735-6. Epub 2022 Dec 13. Lancet Infect Dis. 2023. PMID: 36525985 Free PMC article. Clinical Trial.
Solicited adverse events and the severity of solicited adverse events were not significantly different between groups at day 5, except for increased abdominal pain associated with azithromycin (47 [23%, 95% CI 18 to 29] of 204 participants) compared with placebo (35 [16%, …
Solicited adverse events and the severity of solicited adverse events were not significantly different between groups at day 5, except for i …
Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study.
Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, Cantón R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Monnet DL; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. Grundmann H, et al. Lancet Infect Dis. 2017 Feb;17(2):153-163. doi: 10.1016/S1473-3099(16)30257-2. Epub 2016 Nov 18. Lancet Infect Dis. 2017. PMID: 27866944 Free article.
METHODS: National expert laboratories recruited hospitals with diagnostic capacities, who collected the first ten carbapenem non-susceptible clinical isolates of K pneumoniae or E coli and ten susceptible same-species comparator isolates and pertinent patient and hospital …
METHODS: National expert laboratories recruited hospitals with diagnostic capacities, who collected the first ten carbapenem non-susceptible …
Pneumonia in the very old.
Janssens JP, Krause KH. Janssens JP, et al. Lancet Infect Dis. 2004 Feb;4(2):112-24. doi: 10.1016/S1473-3099(04)00931-4. Lancet Infect Dis. 2004. PMID: 14871636 Review.
Although there are no fundamental differences in pathophysiology and microbiology of the two entities, NHAP tends to be much more severe, because milder cases are not referred to the hospital, and residents of nursing homes often suffer from dementia, multiple comorbiditie …
Although there are no fundamental differences in pathophysiology and microbiology of the two entities, NHAP tends to be much more sev …
Pneumococcal serotype evolution in Western Europe.
Tin Tin Htar M, Christopoulou D, Schmitt HJ. Tin Tin Htar M, et al. BMC Infect Dis. 2015 Oct 14;15:419. doi: 10.1186/s12879-015-1147-x. BMC Infect Dis. 2015. PMID: 26468008 Free PMC article. Review.
Serotypes that are currently more frequent include 24 F, 22 F, 8 and 15A in countries that use PCV13, and serotypes 19A and 3 in countries that use PCV10. Compared with the time before the introduction of higher valent PCVs, to date, there is no single '19A-like' serotype …
Serotypes that are currently more frequent include 24 F, 22 F, 8 and 15A in countries that use PCV13, and serotypes 19A and 3 in countries t …
Molluscum contagiosum virus infection.
Chen X, Anstey AV, Bugert JJ. Chen X, et al. Lancet Infect Dis. 2013 Oct;13(10):877-88. doi: 10.1016/S1473-3099(13)70109-9. Epub 2013 Aug 21. Lancet Infect Dis. 2013. PMID: 23972567 Review.
Extensive and persistent skin infection with the virus can indicate underlying immunodeficiency. Traditional ablative therapies have not been compared directly with newer immune-modulating and specific antiviral therapies. ...
Extensive and persistent skin infection with the virus can indicate underlying immunodeficiency. Traditional ablative therapies have not bee …
Mechanistic inferences from clinical reports of SARS-CoV-2.
Jenkins MM, McCaw TR, Goepfert PA. Jenkins MM, et al. Infect Dis (Lond). 2020 Aug;52(8):527-537. doi: 10.1080/23744235.2020.1769853. Epub 2020 May 27. Infect Dis (Lond). 2020. PMID: 32459123 Free PMC article. Review.
In this review we collate current clinical and immunologic reports, comparing these to reports of previous coronaviruses to identify mechanisms driving progression to severe disease in some patients. ...
In this review we collate current clinical and immunologic reports, comparing these to reports of previous coronaviruses to identify …
662 results